Medigene AG Asset Resilience Ratio
Medigene AG asset resilience ratio. Medigene AG (MDG1) has an Asset Resilience Ratio of 25.22% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Medigene AG defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Medigene AG (2012–2023)
Asset resilience ratio of Medigene AG from 2012 to 2023. This chart shows how Medigene AG's Asset Resilience Ratio has changed over time. Read MDG1 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Medigene AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Medigene AG total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €8.00 Million | 25.22% |
| Total Liquid Assets | €8.00 Million | 25.22% |
Asset Resilience Insights
- Very High Liquidity: Medigene AG maintains exceptional liquid asset reserves at 25.22% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Medigene AG Industry Peers by Asset Resilience Ratio
Compare Medigene AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Medigene AG Asset Resilience Ratio by Year (2012–2023)
Medigene AG asset resilience ratio by year from 2012 to 2023. The table below shows the annual Asset Resilience Ratio data for Medigene AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 25.22% | €8.00 Million ≈ $9.35 Million |
€31.72 Million ≈ $37.08 Million |
-39.07pp |
| 2022-12-31 | 64.29% | €33.22 Million ≈ $38.84 Million |
€51.68 Million ≈ $60.42 Million |
+26.60pp |
| 2021-12-31 | 37.69% | €22.42 Million ≈ $26.21 Million |
€59.47 Million ≈ $69.53 Million |
-2.48pp |
| 2020-12-31 | 40.18% | €30.03 Million ≈ $35.11 Million |
€74.75 Million ≈ $87.39 Million |
-9.89pp |
| 2019-12-31 | 50.07% | €54.68 Million ≈ $63.93 Million |
€109.22 Million ≈ $127.68 Million |
+10.40pp |
| 2018-12-31 | 39.67% | €51.41 Million ≈ $60.10 Million |
€129.59 Million ≈ $151.50 Million |
-6.54pp |
| 2017-12-31 | 46.21% | €51.72 Million ≈ $60.47 Million |
€111.94 Million ≈ $130.87 Million |
-0.90pp |
| 2016-12-31 | 47.11% | €52.63 Million ≈ $61.53 Million |
€111.72 Million ≈ $130.61 Million |
+13.64pp |
| 2015-12-31 | 33.47% | €38.00 Million ≈ $44.43 Million |
€113.53 Million ≈ $132.73 Million |
+33.22pp |
| 2014-12-31 | 0.25% | €180.00K ≈ $210.44K |
€71.28 Million ≈ $83.34 Million |
-0.04pp |
| 2013-12-31 | 0.29% | €154.00K ≈ $180.04K |
€52.66 Million ≈ $61.56 Million |
-0.30pp |
| 2012-12-31 | 0.59% | €362.00K ≈ $423.22K |
€61.26 Million ≈ $71.61 Million |
-- |
About Medigene AG
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications. The company also develop… Read more